In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Integrative high-throughput studies identify novel targets and drugs for advanced prostate cancer treatment Prostate cancer, a prevalent malignancy ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

News, features, and commentary about cancer-related issues ...

Study finds similar safety regardless of anticoagulant type.In a study of adults with advanced prostate cancer taking androgen-receptor pathway ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing partner, Accord Healthcare, that the European Medicines Agency's (EMA) Committee for ...